Your Environment Is Cleaner Your Immune System Has Never Been So Unprepared

Should kids pick their nose? Eat dirt? Avoid antibacterial soap? A dermatologist in Denver who treats people with allergies and autoimmune disorders says definitely “yes!” Believing our world is becoming much too sanitized, Dr. Meg Lemon advises that our immune system is not getting a good workout, and we are therefore more susceptible to allergens. Research going back as far as 1872 agrees with the hypothesis that when the immune system is not properly trained it overreacts and develops allergies, or in other words, chronic immune system attacks.

Your Environment Is Cleaner
Your Immune System Has Never Been So Unprepared

text
A century ago, British scientists suggested a link between increased hygiene and allergic conditions — the first hint that our immune systems are becoming improperly “trained.”
Credit Mike McQuade

By Matt Richtel, March 12, 2019
Excerpted from “An Elegant Defense: The Extraordinary New Science of the Immune System,” published on Tuesday by William Morrow.

Should you pick your nose?

Don’t laugh. Scientifically, it’s an interesting question.

Should your children pick their noses? Should your children eat dirt? Maybe: Your body needs to know what immune challenges lurk in the immediate environment.

Should you use antibacterial soap or hand sanitizers? No. Are we taking too many antibiotics? Yes.

Continue Reading

Could Your Mindset Affect How Well A Treatment Works?

Now that more and more parents are willing to try peanut patches and powders in order to build up an immunity to life-threatening allergies in their children, there are fears about possible side effects. Researchers are finding that when they frame the message that unpleasant side effects are a positive signal that the treatment is working, patients are less likely to drop out of studies and will continue on with the daily regimens.

Could Your Mindset Affect How Well A Treatment Works?

Mindset for Allergy Treatment drawing
Chris Madde/Getty Images

By Esther Landhuis
March 1, 2019

Anxiety about side effects can keep people from starting or sticking to drug regimens or medical procedures. A group of researchers at Stanford University wanted to find out whether a simple mindset shift could help patients tolerate an uncomfortable treatment. They learned that when physicians make the effort to reframe potentially unpleasant symptoms in a positive light, it helped patients to stay calm and persevere.

Continue Reading

StellaPharma to Develop Epinephrine Nasal Spray Product

No one particularly likes needles, including the person administering them and the person receiving medication with them—even in an emergency. So we are pleased to report efforts are being made to develop a dry powder nasal spray of epinephrine to treat anaphylaxis. The Food and Drug Administration (FDA) has already stated that nasal delivery can be an excellent alternative for delivery of rescue medications during life threatening patient events, such as drug overdoses.

StellaPharma to Develop Epinephrine Nasal Spray Product

Young woman using epinephrine nasal spray

News provided by
StellaPharma, Inc.
Jan 15, 2019
RALEIGH, N.C.
PRNewswire

StellaPharma, Inc. (Stella) announced today that it has entered into an agreement whereby Stella will acquire the assets of G2B Pharma (G2B) including IP related to a dry powder nasal formulation of epinephrine being developed for anaphylaxis. Recent U.S. FDA product approvals indicate nasal delivery can be an excellent alternative route for delivery of rescue medications during life threatening patient events.

Continue Reading

DBV Technologies Sets Sights on FDA Resubmission for Peanut Allergy Treatment

Good news! DBV Technologies is preparing to resubmit their application to the Food and Drug Administration (FDA) for a new treatment for peanut allergies in children called Viaskin Peanut, better known as the peanut patch. The company has obtained Fast Track and Breakthrough Therapy designation from the FDA and is planning to submit by the third quarter of this year, a faster than expected timeframe. Meanwhile, rival Aimmune Therapeutics has already submitted their application and may win U.S. approval for its drug ahead of DBV.

DBV Technologies Sets Sights on FDA Resubmission for Peanut Allergy Treatment

Opened peanut shells with peanuts

By Ned Pagliarulo
Feb. 14, 2019

Dive Brief:

DBV Technologies expects to resubmit its experimental treatment for peanut allergy to the Food and Drug Administration by the third quarter of this year, a speedier-than-expected path back to the regulator after the company withdrew its original application last December. 

Continue Reading

Food Allergy-Related Insurance Claims Up in Almost Every State in the Country

One measure of the increasing number of allergies in the U.S. is how many health insurance claims have been filed for anaphylaxis food reactions. A recent study showed that claims rose a whopping 377% from 2007 to 2016! The Food Allergy Research & Education (FARE) group recently launched the Contains: Courage campaign, to drive awareness and raise an unprecedented amount of funding for research, therapies and diagnostics to improve the quality of life of children and adults who are affected.

Food Allergy-Related Insurance Claims Up in Almost Every State in the Country

Health Benefits Claim Form

By News Wire
January 23rd, 2019

McLean, VA – Food Allergy Research & Education (FARE), the largest private funder of food allergy research in the world, today released the results of a study on private insurance claim lines and food allergies. The study showed that claim lines with diagnoses of anaphylactic food reactions rose 377% from 2007 to 2016, and in every state except Massachusetts, claim lines with anaphylactic food reactions and history of food allergy diagnoses represented an increasing share of all medical claim lines from 2009 to 2016. Anaphylaxis is a serious allergic reaction that can occur quickly and is potentially life-threatening.  

Continue Reading

The information provided on this site is in no way intended to be a substitute for medical advice,
diagnosis, or treatment with a licensed physician.
The Allergy Advocacy Association is a 501(c)(3) non-profit, tax-exempt organization.
Copyright 2019 © Allergy Advocacy Association, Inc. All rights reserved.  Terms & Conditions